Imprimis Pharmaceuticals announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate. This new registration will allow Imprimis to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers, including many of the largest ambulatory surgery centers in the US and numerous hospital systems, in order to provide patients and their healthcare professionals with affordable compounded formulations when they are clinically appropriate. By partnering with physicians to meet their patients' unmet needs, Imprimis continues to make progress in meeting its mission of bringing high quality innovative ophthalmic formulations to physicians and their patients.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.